134 related articles for article (PubMed ID: 24507112)
1. [Prognostic factors in renal cell carcinoma].
Wen JJ; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):850-3. PubMed ID: 24507112
[No Abstract] [Full Text] [Related]
2. Prognostic and predictive biomarkers in renal cell carcinoma.
Vickers MM; Heng DY
Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
[TBL] [Abstract][Full Text] [Related]
3. Current status and future directions of molecular markers in renal cell carcinoma.
Rini BI
Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
[TBL] [Abstract][Full Text] [Related]
4. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in renal cell carcinoma.
McGuire BB; Fitzpatrick JM
Curr Opin Urol; 2009 Sep; 19(5):441-6. PubMed ID: 19584732
[TBL] [Abstract][Full Text] [Related]
6. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
[TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
8. Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Bing Z; Lal P; Lu S; Ziober A; Tomaszewski JE
Ann Diagn Pathol; 2013 Feb; 17(1):58-62. PubMed ID: 22898056
[TBL] [Abstract][Full Text] [Related]
9. Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.
Zaldumbide L; Erramuzpe A; Guarch R; Cortés JM; López JI
Virchows Arch; 2015 Jan; 466(1):61-6. PubMed ID: 25369891
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
11. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
12. Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC.
Pickering LM; Larkin J
Nat Rev Urol; 2015 Jun; 12(6):309-10. PubMed ID: 26032554
[No Abstract] [Full Text] [Related]
13. Carbonic anhydrase IX: historical and future perspectives.
Oosterwijk E
BJU Int; 2008 Jun; 101 Suppl 4():2-7. PubMed ID: 18430115
[No Abstract] [Full Text] [Related]
14. [Clear cell papillary renal cell carcinoma: report of a case].
Lin D; Zhang W; Zhao H; Xin F; Li Y; Liu H
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):192-3. PubMed ID: 24842020
[No Abstract] [Full Text] [Related]
15. Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.
Serrano-Oviedo L; Giménez-Bachs JM; Nam-Cha SY; Cimas FJ; García-Cano J; Sánchez-Prieto R; Salinas-Sánchez AS
Urol Oncol; 2017 Mar; 35(3):114.e15-114.e22. PubMed ID: 27836247
[TBL] [Abstract][Full Text] [Related]
16. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Alshenawy HA
Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch B; Li Z; Belldegrun AS
BJU Int; 2008 Jun; 101 Suppl 4():25-30. PubMed ID: 18430119
[No Abstract] [Full Text] [Related]
19. Tissue-based molecular markers for renal cell carcinoma.
Rink M; Chun FK; Robinson B; Sun M; Karakiewicz PI; Bensalah K; Fisch M; Scherr DS; Lee RK; Margulis V; Shariat SF
Minerva Urol Nefrol; 2011 Dec; 63(4):293-308. PubMed ID: 21996985
[TBL] [Abstract][Full Text] [Related]
20. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]